- Monopar Therapeutics Inc MNPR opened enrollment for the fifth dose level cohort in the open-label Phase 1b camsirubicin Maximum Tolerated Dose trial for advanced soft tissue sarcoma (ASTS), a diverse type of cancer that typically develops in the body's connective tissue.
- The cohort dose is at an increased dose of 650 mg/m2, nearly 2.5x the highest dose evaluated in any prior camsirubicin clinical trial.
- The company said that no drug-related cardiotoxicity has been observed with camsirubicin treatment.
- It compares favorably to the well-documented dose-restricting cardiotoxicity experienced with doxorubicin treatment, the current first-line treatment for ASTS.
- 17% of camsirubicin patients in the trial have experienced low-grade hair loss; another 8% have experienced over 50% hair loss, versus approximately 50% of doxorubicin-treated patients reporting some amount of hair loss, with the majority of these patients experiencing >50% hair loss.
- 8% of camsirubicin patients in the trial have experienced low-grade mild oral mucositis compared to the roughly 35-40% of doxorubicin-treated patients.
- "So far, camsirubicin has demonstrated a favorable safety profile at up to the 520 mg/m2 dose level assessed to date," said Dr. Cranmer."
- EF Hutton writes that having established proof-of-concept in sarcoma, camsirubicin could be developed in another dozen cancer indications, where doxorubicin is still the backbone of treatment.
- It reiterates the Buy rating and a price target of $24.
- Price Action: MNPR shares are down 13.7% at $3.16 on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
